Toppublicaties

Longcarcinoom

Geselecteerd door: Longcarcinoom
  • oktober 2022

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

  • Jamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
  • oktober 2022

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

  • Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.
  • oktober 2022

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

  • Shunsuke Kitajima, Tetsuo Tani, Benjamin F Springer, et al.
  • september 2022

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomized, phase 3 trial

  • Virginie Westeel, Pascal Foucher, Arnaud Scherpereel, et al.
  • september 2022

Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose CT Screening

  • Anil Vachani, Nikki M Carroll, Michael J Simoff, et al.
  • september 2022

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

  • Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, et al.
  • augustus 2022

YES1 Is a Druggable Oncogenic Target in SCLC

  • Esther Redin, Eva M Garrido-Martin, Karmele Valencia, et al.
  • augustus 2022

First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report

  • Omid Savari, Jason C Chang, Justin A Bishop, et al.
  • juli 2022

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

  • Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.
Duiding door Prof. dr. Egbert Smit

Moleculaire restziekte voorspelt recidiverisico
  • juli 2022

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

  • Jia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.
  • juni 2022

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

  • Janning M., Süptitz J., Albers-Leischner C.
  • juni 2022

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

  • Majem M., Goldman J W., John T.
Gedownload van https://medischeoncologie.nl/ op 22-03-2023 om 12:57. Copyright (C) 2023 BPM Medica.

Deel deze pagina